CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Free Report) – Stock analysts at William Blair increased their FY2023 earnings per share (EPS) estimates for shares of CymaBay Therapeutics in a report issued on Tuesday, November 7th. William Blair analyst A. Hsieh now forecasts that the biopharmaceutical company will post earnings per share of ($0.97) for the year, up from their prior forecast of ($1.02). The consensus estimate for CymaBay Therapeutics’ current full-year earnings is ($0.92) per share. William Blair also issued estimates for CymaBay Therapeutics’ Q4 2023 earnings at ($0.35) EPS, Q1 2024 earnings at ($0.37) EPS, Q2 2024 earnings at ($0.45) EPS, Q3 2024 earnings at ($0.53) EPS, Q4 2024 earnings at ($0.59) EPS, FY2024 earnings at ($1.93) EPS and FY2025 earnings at ($2.80) EPS.
CymaBay Therapeutics (NASDAQ:CBAY – Get Free Report) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.02). During the same period last year, the company earned ($0.28) earnings per share.
CymaBay Therapeutics Stock Up 9.7 %
CymaBay Therapeutics stock opened at $16.30 on Friday. The firm has a market cap of $1.80 billion, a price-to-earnings ratio of -17.72 and a beta of 0.29. The stock has a fifty day simple moving average of $15.09 and a two-hundred day simple moving average of $12.23. CymaBay Therapeutics has a 12 month low of $3.17 and a 12 month high of $18.20. The company has a current ratio of 22.76, a quick ratio of 12.52 and a debt-to-equity ratio of 0.32.
Institutional Trading of CymaBay Therapeutics
Institutional investors and hedge funds have recently modified their holdings of the company. Arizona State Retirement System bought a new stake in shares of CymaBay Therapeutics during the 1st quarter valued at $214,000. Mirabella Financial Services LLP raised its position in shares of CymaBay Therapeutics by 133.9% during the 1st quarter. Mirabella Financial Services LLP now owns 58,180 shares of the biopharmaceutical company’s stock valued at $507,000 after purchasing an additional 33,307 shares during the period. California State Teachers Retirement System bought a new stake in shares of CymaBay Therapeutics during the 1st quarter valued at $649,000. Moody Aldrich Partners LLC bought a new stake in shares of CymaBay Therapeutics during the 2nd quarter valued at $1,263,000. Finally, Victory Capital Management Inc. bought a new stake in shares of CymaBay Therapeutics during the 1st quarter valued at $88,000. 95.03% of the stock is currently owned by institutional investors.
In related news, insider Charles Mcwherter sold 21,746 shares of the stock in a transaction that occurred on Friday, August 18th. The shares were sold at an average price of $11.47, for a total value of $249,426.62. Following the completion of the sale, the insider now directly owns 15,000 shares of the company’s stock, valued at approximately $172,050. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other CymaBay Therapeutics news, insider Charles Mcwherter sold 21,746 shares of CymaBay Therapeutics stock in a transaction that occurred on Friday, August 18th. The shares were sold at an average price of $11.47, for a total transaction of $249,426.62. Following the transaction, the insider now owns 15,000 shares of the company’s stock, valued at $172,050. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Sujal Shah sold 64,861 shares of the company’s stock in a transaction that occurred on Monday, October 9th. The stock was sold at an average price of $14.20, for a total transaction of $921,026.20. Following the completion of the transaction, the chief executive officer now owns 171,301 shares of the company’s stock, valued at $2,432,474.20. The disclosure for this sale can be found here. Insiders have sold a total of 209,017 shares of company stock valued at $3,101,198 in the last ninety days. Corporate insiders own 7.00% of the company’s stock.
CymaBay Therapeutics Company Profile
CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of autoimmune liver disease, primary biliary cholangitis (PBC).
- Five stocks we like better than CymaBay Therapeutics
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Data giants MongoDB and Snowflake just got upgraded
- Stock Analyst Ratings and Canadian Analyst Ratings
- Plug Power at tipping point; it’s make or break time for hydrogen
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Palantir’s Q3 earnings beat: Time to buy despite analyst caution?
Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.